Submit an Article. Govers C, Sebestyn Z, Coccoris M, Willemsen RA, Debets R. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. . Worst BC, van Tilburg CM, Balasubramanian GP, et al. How Influential is Precision Cancer Medicine? Journal Impact Factor: 1: Cancer Journal For Clinicians: 55,868: 508.702: 2: Nature Reviews Molecular Cell Biology: 58,477: 94.444: 3: New England Journal Of Medicine: 4,64,351: 91.245: 4: Nature Reviews Drug Discovery: 41,989: . Nature Portfolio. In May 2022 Wiley became a signatory of the Declaration on Research Assessment (DORA), which is a world-wide initiative designed to improve the ways in which the outputs of scholarly research are evaluated.. We're supporting responsible research assessment practices by rolling out a broader range of journal and article metrics publicly available, and helping . 21 February 2023. Around the turn of the twentieth century, researchers realized that radiation could be used to treat cancer. This journal has an h-index of 3. In summary, the available biomarkers are insufficient to adequately predict response to immunotherapy. An article for this column could be a Case-Based Review, providing a case with educational values and relevant review of the literature and highlighting the level of evidence supporting key decisions. This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. PCM is an open access journal co-funded by the FUSCC and AME Publishing Company. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Maastricht, Netherlands. CiteScore: 1.9 . We are pleased to announce that the Translational Cancer Research (TCR) has attained its latest impact factor update for the 2020 citation year: 1.241.. Translational Cancer Research (Transl Cancer Res, TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). A major challenge in the therapeutic management of patients with advanced metastatic cancer is the complexity of tumor biology. Garassino M, Rodriguez-Abreu D, Gadgeel S, et al. Tamminga M, de Wit S, Hiltermann TJN, et al. The h-index is a way of measuring the productivity and citation impact of the publications. The editorial structure of the journal is listed as below and the roles and responsibilities of the editorial team are available at: https://www.amegroups.com . Privacy and transmitted securely. An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience, Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study, Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial, High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. AIMS AND SCOPE. Cancer treatments that target the characteristics of an individual's tumour could have a wider impact. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. The impact score (IS) 2021 of Precision Cancer Medicine is 0.34, which is computed in 2022 as per its definition. Guidelines for the validation of NGS panels36 and the interpretation and reporting of genomic variants have been developed37. Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? As there are several TKIs, upon progression, the optimal sequential ALK and ROS-1 TKI strategy at progression is relevant, and this may have an impact on patients' outcome. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative, Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses, Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. 5-year Impact Factor . The Centers for Disease Control and Prevention project that by 2030 cancer will surpass CVD as the leading cause of .
Interestingly, matching patients to drugs on the basis of genomics has proven more effective in improving outcome than matching on the basis of protein assays, perhaps for technical reasons24. Esserman LJ, Berry DA, DeMichele A, et al. Von Hoff DD, Stephenson JJ Jr., Rosen P, et al. Get the most important science stories of the day, free in your inbox. Precision Cancer Medicine is a journal covering the technologies/fields/categories related to Anesthesiology and Pain Medicine (Q3); Pharmacology (medical) (Q3); Surgery (Q3); Cancer Research (Q4); Oncology (Q4); Oncology (nursing) (Q4). Skip to main content. van Rooij N, van Buuren MM, Philips D, et al. 152OFirst report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts), Signature program: a platform of basket trials, Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289). It is based on Scopus data. Precision oncology has tended to focus on the cancer genome, but also taking into account RNA and proteins, for example, could identify new options for targeted treatments. Herein, we review the rapid evolution of precision medicine in oncology and, in particular, the challenge and opportunity that genomic science has revealed vis--vis the need for N-of-1 treatments. About this content. As a library, NLM provides access to scientific literature. Approximately 35% of patients with cancer are enrolled on clinical trials and accrual is limited by overly restrictive eligibility criteria and limited access to drugs.114 ASCO, the Friends of Cancer Research, and the FDA recommended to broaden eligibility criteria to allow more patients to participate in clinical trials and gain benefit from novel investigational therapies;115 and consequently participants will be representative of the actual patient population, increasing generalizability of the results. Genomic biomarkers have been the most successful to date, but other biomarkers, including protein assays and transcriptomics, are being developed and tested.13,24,25 Several molecular alterations have been identified using sequencing and high-throughput technologies and have led to the approval of targeted agents by the Food and Drug Administration (FDA).26,27 Importantly, in recent years, the precision medicine paradigm has embraced immunotherapy and its interaction with genomics, as genomic characteristics, such as mismatch repair gene defects, are critical predictors of checkpoint blockade response.2830. . Aims and Scope. SCImago Journal Rank (SJR indicator) is a measure of scientific influence With the current excitement about the promise of immunotherapy, a large proportion of patients are assigned to immunotherapy trials without undergoing molecular profiling or immune marker identification. Precision Cancer Medicine is a journal covering the technologies/fields/categories related to Anesthesiology and Pain Medicine (Q3); Pharmacology (medical) (Q3); Surgery (Q3); Cancer Research (Q4); Oncology (Q4); Oncology (nursing) (Q4). Conferences Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells, Chimeric antigen receptor T cells for sustained remissions in leukemia, ACTolog in Patients With Solid Cancers (ACTolog), {"type":"clinical-trial","attrs":{"text":"NCT02876510","term_id":"NCT02876510"}}, Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. the productivity and citation impact of the publications of a Importantly, malignancies have complicated molecular biology, and use of personalized combinations of drugs that address a higher percentage of the aberrations present in an individual cancer is associated with better outcomes than more limited matching.6,7,12,13, Other major hurdles encountered in the implementation of precision medicine include the following: (i) Potential differences in response to matched therapy depending on histology and/or genomic co-alterations. You can start . A comparative study of five prospective randomized phase III trials in 6,081 patients with metastatic castration-resistant prostate cancer assessed the prognostic value of CTCs compared to prostate-specific antigen.49 CTC 0 at baseline and at week 13 from treatment initiation was associated with OS. CiteScore. According to the Journal Citation Reports, the journal has a 2020 impact factor of 4.452. Directory of Open Access Journals (DOAJ) Colorectal Cancer. Phase III randomized trials were often critical for regulatory approval of a novel agent/regimen, especially since the antitumor activity of a new drug/regimen was frequently only marginally better than the comparator arm (usually, conventional therapy), perhaps because the regimen was effective in only a small subgroup of the diverse population represented by any specific histology. BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. Some solutions provided by trials with higher matching rates, e.g., I-PREDICT12 (matching rate, 49%), include: (i) use of clinical trial navigators and medication acquisition specialists; (ii) application of a large NGS panel with >200 genes; (iii) creation of just-in-time electronic molecular tumor boards immediately upon physician request; and (iv) exploitation of biomarkers to match patients to chemotherapy, hormonal therapy, and immunotherapy (in addition to gene-targeted agents). * Required. Primary lung secretory carcinoma: a case report, Trastuzumab-Pertuzumab resistance in a case of HER2-del16 expressing colorectal cancera case report. Historically, phase II and III oncology clinical trials have measured outcomes histologically, but histological assessment cannot always capture the effects of gene-targeted agents or immunotherapy. By the end of 2020, 1.8 million people in the United States were diagnosed with cancer, 5% of whom will be at high risk for heart disease. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients, Tumour heterogeneity and resistance to cancer therapies, Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. We extend such ana Molecular characterization has the potential to advance the management of pediatric cancer and high-risk hematologic disease. In high-grade serous ovarian cancer (HGSOC), intrinsic and/or acquired resistance against platinum-containing chemotherapy is a major obstacle for successful treatment. The Chinese University of Hong Kong, Shenzhen (CUHK Shenzhen). SJR is a measure of scientific influence of journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from
About this Journal. Genomic studies have unveiled the reality of tumorsthey are tremendously heterogeneic and complex, and optimized therapy often does not result from classical clinical research and practice models. The complexity is amplified by the dynamic, Darwinian evolutionary character of cancer cells, which undergo sequential searches for mechanisms to escape environmental constraints. Genome Medicine is pleased to present a special issue on Precision Cancer Medicine. Mechanisms of acquired resistance knowledge will be also relevant to develop new personalized treatment strategies to overcome in the near future. Nature Reviews Cancer is a journal covering the categories related to Cancer Research (Q1); Oncology (Q1).It is published by Nature Publishing Group.The overall rank of Nature Reviews Cancer is 21.ISSN of this journal is/are 1474175X, 14741768.. Impact Score: 27.46 h-Index: 462 SJR: 16.955 Overall Ranking: 21. Impact Factor: 2.498 (2021) Impact Factor ranking: 113 of 139 (Medicine, Research & Experimental) 5-Year Impact Factor: 2.801 (2021) . In 2001, the human genome was sequenced.33 Although this milestone represented an arduous and tremendously expensive endeavour, both the price and time required for sequencing have decreased precipitously, with technology advancing in a manner unparalleled in human history. Precision Cancer Medicine (PCM, Precis Cancer Med, ISSN: 2617-2216) is an open access, peer-reviewed online journal dedicated to precise diagnosis and treatment of cancers and personalized care for patients. Ownership interest: IDbyDNA and Curematch, Inc. National Library of Medicine We are pleased to announce that the Translational Cancer Research (TCR) has attained its latest impact factor update for the 2021 citation year: 0.496. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Through this web page, researchers can check the impact factor, total citation, journal quartile, and journal aim & scope. We are pleased to present the 2022 Annual Report of Precision Cancer Medicine (PCM). Remarkable biotechnological advances are transforming cancer care. International Scientific Journal & Country Ranking. By reactivating the innate immune antitumor response, immunotherapy has provided a major breakthrough in oncology treatment.28,59 Several novel approaches are currently being explored: checkpoint blockade, oncolytic viruses, cell-based products, modified cytokines, CD3-bispecific antibodies, vaccine platforms, and adoptive cell therapy.60, There are seven FDA-approved checkpoint inhibitors: ipilimumab, pembrolizumab, nivolumab, avelumab, cemiplimab, durvalumab, and atezolizumab. Hence, it can provide a rough estimation only. An ISSN is a unique code of 8 digits. With advanced computer data processing capabilities, real-world registries and data mining are expanding. 8600 Rockville Pike Patient enrollment could be enhanced by national and worldwide collaborations, as shown in multi-institutional trials.116,117 Finally, the Clinical Trials Transformation Initiative (CTTI), has been developed to examine the challenges and propose solutions to improve trial recruitment.118. JCO Precision Oncology showcases high-quality, original documents where all submitted articles are peer reviewed . A multidisciplinary journal which advances our medical knowledge. But, as some people with cancer are already finding out, there is another way. Abd Elmageed ZY, Yang Y, Thomas R, et al. 2017. Hainsworth JD, Meric-Bernstam F, Swanton C, et al. As a service to our customers we are providing this early version of the manuscript. (2 years)). This article is part of Nature Outlook: Precision Oncology, an editorially independent supplement produced with the financial support of third parties. Zeynep Kalender Atak, Hana Imrichova, Dmitry Svetlichnyy, Gert Hulselmans, Valerie Christiaens, Joke Reumers, Hugo Ceulemans and Stein Aerts, Kenneth D. Doig, Andrew Fellowes, Anthony H. Bell, Andrei Seleznev, David Ma, Jason Ellul, Jason Li, Maria A. Doyle, Ella R. Thompson, Amit Kumar, Luis Lara, Ravikiran Vedururu, Gareth Reid, Thomas Conway, Anthony T. Papenfuss and Stephen B. Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/, Journal Impact Factor, https://clarivate.com/. Journal Metrics: Cancer Medicine. The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. Before Comoli P, Pedrazzoli P, Maccario R, et al. Biochemistry, Genetics and Molecular Biology, Pharmacology, Toxicology and Pharmaceutics, EU Parliament Roe v. Wade Resolution Vote, LaTeX Installation Guide Easy to Follow Steps to Install LaTeX, 6 Easy Steps to Create Your First LaTeX Document. Ca-A Cancer Journal for Clinicians is a journal covering the categories related to Hematology (Q1); Oncology (Q1).It is published by Wiley-Blackwell.The overall rank of Ca-A Cancer Journal for Clinicians is 1.ISSN of this journal is/are 15424863, 00079235.. Impact Score: 186.75 h-Index: 182 SJR: 56.204 Overall Ranking: 1 Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma, Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial, Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcolor platform. Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences, in the areas of, but not limited to, cancer biology, clinical cancer research, and cancer prevention. Therefore, the incorporation of biomarkers into the selection of patients for immunotherapy needs to be optimized. See all (441) Maastricht University Medical Centre. 3. General Genetics and Molecular Biology and Oncology and Cancer Research. This collection of articles has not been sponsored and articles have undergone the journals standard peer-review process. Bioxbio.com includes the journal factors, ISSN, number of articles and other detailed information of over 11000 journals in different fields. Nature (Nature) A comparative study of five prospective randomized phase III trials in 6,081 patients with metastatic castration-resistant prostate cancer assessed the prognostic value of CTCs compared to prostate-specific antigen. Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. Beyond genomics, RNA and protein profiling, with proteins being the effectors of signaling, also appear to be important in mediating biologic impact. Failure to match patients is attributed to (i) enrollment of individuals with end-stage disease, who deteriorate or die early; (ii) use of small gene panels that yield limited actionable alterations; (iii) delays in receiving and interpreting genomic results; and (iv) difficulty accessing targeted therapy drugs and/or limited drug availability. Springer Nature. Seminars Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate, Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy, STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment, Melanoma-intrinsic -catenin signalling prevents anti-tumour immunity. Impact Factor NA H Index 3 Impact Factor 0.342 I. Accessibility Postdoctoral Research Fellow at the Dalian Institute of Chemical Physics, Professor/Associate Professor/Assistant Professor/Senior Lecturer/Lecturer, Faculty Positions at SUSTech Department of Biomedical Engineering. The Guest editors declare no competing interests. Improved pCR rates in 2 study arms with drug addition: Results for 2 arms of I-SPY-2 study available, Improved PFS and OS with matched vs unmatched therapy (p<0.0001), The trial included 10 phase II trials that operated independently (based on eight biomarkers), Ongoing study with preliminary results (see, Direct sequencing, FISH, CLIA certified genotyping, Advanced cancers including treatment-nave patients, NGS correlational testing: whole genomic, transcriptome, liquid biopsy (ctDNA), and immune signature, Columbia University N- of-1 Clinical Trials, Computational strategies (OncoTarget and OncoTreat). The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. The recently launched Cancer Research Communications (CRC) is the latest addition to the AACR's journal portfolio. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657, Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER), Adaptive Randomization of Neratinib in Early Breast Cancer, Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer, Unique molecular landscapes in cancer: implications for individualized, curated drug combinations, Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes, Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. The acceptance rate/percentage of any academic journal/conference depends upon many parameters. The demand or interest of researchers/scientists in publishing in a specific Journal/Conference. The clinical integration of genome sequencing into standard clinical practice has b Comprehensive genomic sequencing (CGS) has the potential to revolutionize precision medicine for cancer patients across the globe. Follow us on @ScimagoJRScimago Lab, Copyright 2007-2022. Forum. It is time to recognize the possibility that advanced computer implementation could generate real-world data that expand our understanding of cancer, rapidly identify new treatments, and create personalized drugs or immune therapies. Fox, Zachary R. Chalmers, Caitlin F. Connelly, David Fabrizio, Laurie Gay, Siraj M. Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki, Franklin Huang, Yuting He, James Sun, Uri Tabori, Mark Kennedy, Daniel S. Lieber, David J. Duffy, Aleksandar Krstic, Melinda Halasz, Thomas Schwarzl, Anja Konietzny, Kristiina Iljin, Desmond G. Higgins and Walter Kolch, E. Zeynep Erson-Omay, Octavian Henegariu, S. Blent Omay, Akdes Serin Harmanc, Mark W. Youngblood, Ketu Mishra-Gorur, Jie Li, Koray zduman, Geneive Carrin-Grant, Victoria E. Clark, Caner alar, Mehmet Bakrcolu, M. Necmettin Pamir, Viviane Tabar, Alexander O. Vortmeyer, Kaya Bilguvar, Jianjiong Gao, Matthew T. Chang, Hannah C. Johnsen, Sizhi Paul Gao, Brooke E. Sylvester, Selcuk Onur Sumer, Hongxin Zhang, David B. Solit, Barry S. Taylor, Nikolaus Schultz and Chris Sander, Jennifer A. Oberg, Julia L. Glade Bender, Maria Luisa Sulis, Danielle Pendrick, Anthony N. Sireci, Susan J. Hsiao, Andrew T. Turk, Filemon S. Dela Cruz, Hanina Hibshoosh, Helen Remotti, Rebecca J. Zylber, Jiuhong Pang, Daniel Diolaiti, Carrie Koval, Stuart J. Andrews, James H. Garvin, Masayuki Nagahashi, Toshifumi Wakai, Yoshifumi Shimada, Hiroshi Ichikawa, Hitoshi Kameyama, Takashi Kobayashi, Jun Sakata, Ryoma Yagi, Nobuaki Sato, Yuko Kitagawa, Hiroyuki Uetake, Kazuhiro Yoshida, Eiji Oki, Shin-ei Kudo, Hiroshi Izutsu, Keisuke Kodama, Chengliang Dong, Yunfei Guo, Hui Yang, Zeyu He, Xiaoming Liu and Kai Wang, Jonathan R. Dry, Mi Yang and Julio Saez-Rodriguez, Deborah I. Ritter, Sameek Roychowdhury, Angshumoy Roy, Shruti Rao, Melissa J. Landrum, Dmitriy Sonkin, Mamatha Shekar, Caleb F. Davis, Reece K. Hart, Christine Micheel, Meredith Weaver, Eliezer M. Van Allen, Donald W. Parsons, Howard L. McLeod, Michael S. Watson, Sharon E. Plon, Filemon S. Dela Cruz, Daniel Diolaiti, Andrew T. Turk, Allison R. Rainey, Alberto Ambesi-Impiombato, Stuart J. Andrews, Mahesh M. Mansukhani, Peter L. Nagy, Mariano J. Alvarez, Andrea Califano, Farhad Forouhar, Beata Modzelewski, Chelsey M. Mitchell, Darrell J. Yamashiro, Lianna J.